Table 3.
Univariable and multivariable Cox regression analysis for Group Lobe of stage 1 NSCLC patients (n = 1,292).
| Overall survival | Disease-free survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | |||||
| Variables | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Sex | ||||||||
| Female | Reference | Reference | Reference | |||||
| Male | 1.559(1.212–2.006) | <0.001 | 1.261(0.937–1.696) | 0.126 | 1.191(0.966–1.468) | 0.102 | ||
| Age(years) | 1.030(1.018–1.042) | <0.001 | 1.027(1.015–1.039) | <0.001 | 1.010(1.000–1.020) | 0.040 | 1.009(0.999–1.019) | 0.081 |
| Histology | ||||||||
| SCC | Reference | Reference | Reference | |||||
| Non-SCC | 0.867(0.673–1.117) | 0.269 | 1.294(1.008–1.660) | 0.043 | 1.440(1.109–1.871) | 0.006 | ||
| Differentiation | ||||||||
| Poor–None | Reference | Reference | Reference | |||||
| Well–Moderate | 0.687(0.549–0.861) | <0.001 | 0.748(0.591–0.946) | 0.015 | 0.836(0.683–1.023) | 0.082 | ||
| Tumor size(cm) | 1.269(1.128–1.427) | <0.001 | 1.070(0.928–1.234) | 0.350 | 1.203(1.086–1.332) | <0.001 | 1.090(0.968–1.227) | 0.155 |
| Smoking history | ||||||||
| No | Reference | Reference | Reference | |||||
| Yes | 1.385(1.106–1.733) | 0.004 | 1.070(0.928–1.394) | 0.615 | 1.230(1.009–1.501) | 0.041 | ||
| Pathological stage | ||||||||
| 1A1 | Reference | Reference | Reference | Reference | ||||
| 1A2 | 2.347(0.835–6.595) | 0.105 | 2.19(0.771–6.220) | 0.141 | 2.803(1.005–7.817) | 0.049 | 2.016(0.854–4.757) | 0.110 |
| 1A3 | 2.449(0.869–6.902) | 0.090 | 2.040(0.703–5.924) | 0.190 | 4.211(1.524–11.635) | 0.006 | 2.870(1.205–6.835) | 0.017 |
| 1B | 3.544(1.318–9.529) | 0.012 | 2.999(1.051–8.442) | 0.038 | 5.277(1.967–14.158) | 0.001 | 3.418(1.471–7.947) | 0.004 |
| Bronchus invasion | ||||||||
| No | Reference | Reference | Reference | |||||
| Yes | 1.286(1.010–1.638) | 0.042 | 1.350(1.047–1.741) | 0.021 | 1.077(0.864–1.344) | 0.510 | ||
| Adjuvant therapy | ||||||||
| No | Reference | Reference | Reference | |||||
| Yes | 0.701(0.497–0.988) | 0.042 | 0.668(0.469–0.952) | 0.025 | 1.074(0.822–1.404) | 0.610 | ||
| Surgical approach | ||||||||
| Lobectomy | Reference | Reference | ||||||
| Biolobectomy | 0.619(0.256–1.498) | 0.287 | 0.866(0.447–1.677) | 0.669 | ||||
| Pneumonectomy | 1.233(0.549–2.769) | 0.611 | 1.005(0.476–2.122) | 0.990 | ||||
| EGFR mutation | ||||||||
| Negative | Reference | Reference | Reference | |||||
| Positive | 0.430(0.241–0.767) | 0.004 | 0.506(0.279–0.920) | 0.025 | 1.188(0.831–1.697) | 0.345 | ||
| ALK mutation | ||||||||
| Negative | Reference | Reference | ||||||
| Positive | 0.738(0.101–5.374) | 0.738 | 1.805(0.661–4.930) | 0.250 | ||||
| LN dissection group | ||||||||
| Group A | Reference | Reference | Reference | Reference | ||||
| Group B | 0.637(0.462–0.879) | 0.006 | 0.668(0.483–0.923) | 0.015 | 0.674(0.506–0.897) | 0.007 | 0.737(0.553–0.983) | 0.038 |
| Group C | 0.712(0.553–0.916) | 0.008 | 0.770(0.596–0.996) | 0.046 | 0.893(0.712–1.121) | 0.330 | 0.956(0.761–1.201) | 0.700 |
| Group D | 2.033(0.992–4.164) | 0.053 | 1.649(0.791–3.436) | 0.182 | 2.133(1.084–4.198) | 0.028 | 1.842(0.923–3.673) | 0.083 |
| Group E | 0.152(0.021–0.967) | 0.048 | 0.163(0.022–0.998) | 0.049 | 0.440(0.154–0.891) | 0.037 | 0.468(0.073–0.978) | 0.047 |
ALK, anaplastic lymphoma kinase; CI, confidence interval; cm, centimeter; EGFR, epidermal growth factor receptor; HR, hazard ratio; LN, lymph node; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma.